Abstract
Anticonvulsant drugs (ACs) have diverse antiseizure, psychotropic, and biochemical effects. Carbamazepine and valproate have mood-stabilizing actions, benzodiazepines and gabapentin have anxiolytic actions, lamotrigine is useful in rapid cycling and acute treatment and prophylaxis of bipolar depression, and topiramate and zonisamide can yield weight loss. Limited controlled data suggest the carbamazepine keto derivative oxcarbazepine has antimanic effects. A categorical approach to the diverse roles of ACs in bipolar disorders is proposed, using broad categories of ACs, on the basis of their predominant psychotropic profiles. Thus, some ACs have “sedating” profiles that may include sedation, cognitive difficulties, fatigue, weight gain, and possibly antimanic and/or anxiolytic effects. In contrast, some newer ACs have “activating” profiles that may include improved energy, weight loss, and possibly antidepressant and even anxiogenic effects. Still other newer ACs have novel “mixed” profiles, combining sedation and weight loss. A categorical–mechanistic extension of this approach is also presented, with hypotheses that “sedating” profiles might be related to prominent potentiation of gamma-aminobutyric acid (GABA) inhibitory neurotransmission, “activating” profiles could be related to prominent attenuation of glutamate excitatory neurotransmission, and for “mixed” profiles, sedation and weight loss might be related to concurrent GABAergic and antiglutamatergic actions, respectively. The categorical approach may have utility as an aid to clinicians in reinforcing the heterogeneity ACs, and recalling psychotropic profiles of individual ACs, but is limited as it fails to address the etiology of the heterogeneity of AC psychotropic effects. The categorical–mechanistic extension strives to address this issue, but requires systematic clinical investigation of more precise relationships between psychotropic profiles and discrete mechanisms of action to assess its merits.
Similar content being viewed by others
References
Ketter TA, Kimbrell TA, George MS, Sachs N, Wang PW, Post RM: Predictors of treatment response in bipolar disorder: Evidence from clinical and PET studies. J Clin Psychiatry 2002; 63(Suppl 3):21-25
American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159(4 Suppl):1-50
Petty F: GABA and mood disorders: A brief review and hypothesis. J Affect Disord 1995; 34(4):275-281
Motohashi N, Ikawa K, Kariya T: GABAB receptors are up-regulated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders? Eur J Pharmacol 1989; 166(1):95-99
Motohashi N: GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16(4):571-579
Bernasconi R: The GABA hypothesis of affective illness: Influence of clinically effective antimanic drugs on GABA turnover. In: Emrich HM, Aidenhoff JB, Lux HD, eds. Basic Mechanisms in the Action of Lithium, Proceedings of a symposium, Bavaria, Oct 4–6, 1981. Amsterdam: Elsevier Science; 1982:183-192
Bernasconi R, Hauser K, Martin P, Shcmutz M: Biochemical aspects of the mechanism of action of valproate. In: Emrich HM, Okuma T, Müller AA, eds. Anticonvulsants in Affective Disorders. Amsterdam: Elsevier Science; 1984:14-32
Post RM, Ketter TA, Joffe RT, Kramlinger KL: Lack of beneficial effects of l-baclofen in affective disorder. Int Clin Psychopharmacol 1991; 6(4):197-207
Pope HG, Jr, McElroy SL, Keck PE, Jr, Hudson JI: Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991; 48(1):62-68
Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Treviño ES, Risch SC, Goodnick PJ, Morris DD: (The Depakote Mania Study Group): Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 1994; 271(12):918-924
Winsberg ME, DeGolia SG, Strong CM, Ketter TA: Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001; 67(1–3):207-212
Ketter TA, Calabrese JR: Stabilization of mood from below versus above baseline in bipolar disorder: A new nomenclature. J Clin Psychiatry 2002; 63(2):146-151
Andersen T, Lingjaerde O: Nitrazepam (Mogadon) as a sleep-inducing agent. An analysis based on a double-blind comparison with phenobarbitone. Br J Psychiatry 1969; 115(529):1393-1397
Ballenger JC, Burrows GD, DuPont RL, Jr, Lesser IM, Noyes R, Jr, Pecknold JC, Rifkin A, Swinson RP: Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial, I: Efficacy in short-term treatment. Arch Gen Psychiatry 1988; 45(5):413-422
Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM: Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999; 19(4):341-348
Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T: Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20(4):467-471
Bradwejn J, Shriqui C, Koszycki D, Meterissian G: Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990; 10(6):403-408
Pande AC, Crockatt J, Janney CA, Werth JL, Tsaroucha G (Gabapentin Bipolar Disorder Study Group): Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Bipolar Disord 2000; 2(3, pt 2):249-255
Rickels K, Chung HR, Csanalosi IB, Hurowitz AM, London J, Wiseman K, Kaplan M, Amsterdam JD: Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry 1987; 44(10):862-866
Wang PW, Santosa C, Schumacher M, Winsberg ME, Strong C, Ketter TA: Gabapentin augmentation therapy in bipolar depression. Bipolar Disord 2002; 4(5):296-301
Kaiya H, Namba M, Yoshida H, Nakamura S: Plasma glutamate decarboxylase activity in neuropsychiatry. Psychiatry Res 1982; 6(3):335-343
Nowak G, Ordway GA, Paul IA: Alterations in the N-methyl-D-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995; 675(1–2):157-164
Auer DP, Putz B, Kraft E, Lipinski B, Schill J, Holsboer F: Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 2000; 47(4):305-313
Goff DC, Coyle JT: The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001; 158(9):1367-1377
Cai Z, McCaslin PP: Amitriptyline, desipramine, cyproheptadine and carbamazepine, in concentrations used therapeutically, reduce kainate-and N-methyl-D-aspartate-induced intracellular Ca2+ levels in neuronal culture. Eur J Pharmacol 1992; 219(1):53-57
Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA: Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 1993; 265(3):1380-1386
Gottesfeld Z: Effect of lithium and other alkali metals on brain chemistry and behavior, I: Glutamic acid and GABA in brain regions. Psychopharmacologia 1976; 45(3):239-242
Marcus SR, Nadiger HA, Chandrakala MV, Rao TI, Sadasivudu B: Acute and short-term effects of lithium on glutamate metabolism in rat brain. Biochem Pharmacol 1986; 35(3):365-369
Hokin LE, Dixon JF, Los GV: A novel action of lithium: Stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl D-aspartate receptor in monkey and mouse cerebral cortex slices. Adv Enzyme Regul 1996; 36:229-244
Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD: (Lamictal 602 Study Group): A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60(2):79-88
Twyman RE, Rogers CJ, Macdonald RL: Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989; 25(3):213-220
MacKinnon DF, Zandi PP, Cooper J, Potash JB, Simpson SG, Gershon E, Nurnberger J, Reich T, DePaulo JR: Comorbid bipolar disorder and panic disorder in families with a high prevalence of bipolar disorder. Am J Psychiatry 2002; 159(1):30-35
Lampe H, Bigalke H: Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport 1990; 1(1):26-28
Post RM: Time course of clinical effects of carbamazepine: Implications for mechanisms of action. J Clin Psychiatry 1988; 49(4 Suppl):35-48
Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP: Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002; 27(1–2):121-130
Ketter TA, Post RM, Pazzaglia PJ, Marangell LB, George MS, Callahan AM: Carbamazepine. In: Goodnick P, ed. Mania: Clinical and Research Perspectives. Washington: American Psychiatric Press: 1998:263-300
Post RM, Uhde TW, Roy-Byrne PP, Joffe RT: Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143(1):29-34
Uhde TW, Stein MB, Post RM: Lack of efficacy of carbamazepine in the treatment of panic disorder. Am J Psychiatry 1988; 145(9):1104-1109
Mattson RH, Cramer JA, Collins JF: (The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group): A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl J Med 1992; 327(11):765-771
Rattya J, Vainionpaa L, Knip M, Lanning P, Isojarvi JI: The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999; 103(3):588-593
Ketter TA, Post RM, Worthington K: Principles of clinically important drug interactions with carbamazepine, Part I. J Clin Psychopharmacol 1991; 11(3):198-203
Ketter TA, Post RM, Worthington K: Principles of clinically important drug interactions with carbamazepine, Part II. J Clin Psychopharmacol 1991; 11(5):306-313
Tohen M, Castillo J, Baldessarini RJ, Zarate C, Jr, Kando JC: Blood dyscrasias with carbamazepine and valproate: A pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry 1995; 152(3):413-418
Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B: Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18(6):455-460
Löscher W: Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999; 58(1):31-59
Keck PE, Jr, Taylor VE, Tugrul KC, McElroy SL, Bennett JA: Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993; 33(7):542-546
Hirschfeld RM, Allen MH, McEvoy JP, Keck PE, Jr, Russell JM: Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 1999; 60(12):815-818
Bowden CL, Janicak PG, Orsulak P, Swann AC, Davis JM, Calabrese JR, Goodnick P, Small JG, Rush AJ, Kimmel SE, Risch SC, Morris DD: Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153(6):765-770
Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Jr, Chou JC, Keck PE, Jr, Rhodes LJ, Swann AC, Hirschfeld RM, Wozniak PJ (Divalproex Maintenance Study Group): A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57(5):481-489
Ketter TA, Malow BA, Flamini R, Ko D, White SR, Post RM, Theodore WH: Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 1996; 23(2):129-137
Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH: The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39(1):95-99
Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ, Boden P, Singh L: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29(3):233-249
Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996; 271(10):5768-5776
Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Corá-Locatelli G, Leverich GS, Post RM: A placebo controlled evaluation of lamotrigine and gabapentin monotherapy in mood disorders. J Clin Psychopharmacology 2000; 20(4):607-614
Frye MA, Kimbrell TA, Dunn RT, Piscitelli S, Grothe D, Vanderham E, Corá-Locatelli G, Post RM, Ketter TA: Gabapentin does not alter single-dose lithium pharmacokinetics. J Clin Psychopharmacol 1998; 18(6):461-464
Backonja MM: Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: A multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia 1999; 40(Suppl 6):S57-S59
Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L: Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. JAMA 1998; 280(21):1837-1842
Xie X, Hagan RM: Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998; 38(3):119-130
Ketter TA, Manji HK, Post RM: Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol (in press)
Marson AG, Kadir ZA, Hutton JL, Chadwick DW: The new antiepileptic drugs: A systematic review of their efficacy and tolerability. Epilepsia 1997; 38(8):859-880
Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD, Goodwin FK, Frye MA, Kusumakar V: Rash in multicenter trials of lamotrigine in mood disorders: Clinical relevance and management. J Clin Psychiatry 2002; 63(11):1012-1019
Warner T, Patsalos PN, Prevett M, Elyas AA, Duncan JS: Lamotrigine-induced carbamazepine toxicity: An interaction with carbamazepine-10,11-epoxide. Epilepsy Res 1992; 11(2):147-150
Malminiemi K, Keranen T, Kerttula T, Moilanen E, Ylitalo P: Effects of short-term lamotrigine treatment on pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther 2000; 38(11):540-545
Anderson GD, Yau MK, Gidal BE, Harris SJ, Levy RH, Lai AA, Wolf KB, Wargin WA, Dren AT: Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996; 60(2):145-156
Kaufman KR, Gerner R: Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7(2):163-165
Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET (Lamictal 614 Study Group): A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61(11):841-850
Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE: An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41(Suppl 1):S3-S9
White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH: Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997; 28(3):167-179
Petroff OA, Hyder F, Mattson RH, Rothman DL: Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 1999; 52(3):473-478
Kanda T, Kurokawa M, Tamura S, Nakamura J, Ishii A, Kuwana Y, Serikawa T, Yamada J, Ishihara K, Sasa M: Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER). Life Sci 1996; 59(19):1607-1616
Rosenfeld WE: Topiramate: A review of preclinical, pharmacokinetic, and clinical data. Clin Ther 1997; 19(6):1294-1308
Rhee DJ, Goldberg MJ, Parrish RK: Bilateral angle-closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol 2001; 119(11):1721-1723
Rosenfeld WE, Doose DR, Walker SA, Nayak RK: Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997; 38(3):317-323
Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, Reife R, Kramer L, Pledger G, Karim R: Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 37(6):539-543
McElroy SL, Arnold LM, Shapira NA, Keck PE, Jr, Rosenthal NR, Karim MR, Kamin M, Hudson JI: Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial. Am J Psychiatry 2003; 160(2):255-261
Calabrese JR, Keck PE, Jr, McElroy SL, Shelton MD: A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol 2001; 21(3):340-342
McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH: Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar Disord 2002; 4(3):207-213
Meldrum BS, Chapman AG: Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia 1999; 40(Suppl 9):S2-S6
Kaufman KR: Adjunctive tiagabine treatment of psychiatric disorders: Three cases. Ann Clin Psychiatry 1998; 10(4):181-184
Schaffer L, Schaffer C, Howe J: An open case series on the utility of tiagabine as an augmentation in refractory bipolar outpatients. J Affect Disord 2002; 71(1–3):259
Physicians' desk reference, 57th ed. Montvale, NJ: Thomson PDR; 2003
Grunze H, Erfurth A, Marcuse A, Amann B, Normann C, Walden J: Tiagabine appears not to be efficacious in the treatment of acute mania. J Clin Psychiatry 1999; 60(11):759-762
Schapel G, Chadwick D: Tiagabine and non-convulsive status epilepticus. Seizure 1996; 5(2):153-156
Emrich HM: Studies with (Trileptal) oxcarbazepine in acute mania. Int Clin Psychopharmacology 1990; 5(Suppl 1):83-88
Friis ML, Kristensen O, Boas J, Dalby M, Deth SH, Gram L, Mikkelsen M, Pedersen B, Sabers A, Worm-Petersen J, Andersen D, Jensen PK: Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87(3):224-227
Smith PE: Clinical recommendations for oxcarbazepine. Seizure 2001; 10(2):87-91
Baruzzi A, Albani F, Riva R: Oxcarbazepine: Pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35(3):S14-S19
Keranen T, Jolkkonen J, Jensen PK, Menge GP, Andersson P: Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 1992; 86(2):120-123
Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E: Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40(6):783-787
Oommen KJ, Mathews S: Zonisamide: A new antiepileptic drug. Clin Neuropharmacol 1999; 22(4):192-200
Mimaki T, Suzuki Y, Tagawa T, Karasawa T, Yabuuchi H: Interaction of zonisamide with benzodiazepine and GABA receptors in rat brain. Med J Osaka Univ 1990; 39(1–4):13-17
Okada M, Kawata Y, Mizuno K, Wada K, Kondo T, Kaneko S: Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998; 124(6):1277-1285
Chadwick DW, Marson AG: Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002(2):CD001416
Kanba S, Yagi G, Kamijima K, Suzuki T, Tajima O, Otaki J, Arata E, Koshikawa H, Nibuya M, Kinoshita N, Asai M: The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18(4):707-715
Nash EM, Sangha KS: Levetiracetam. Am J Health Syst Pharm 2001; 58(13):1195-1199
Zona C, Niespodziany I, Marchetti C, Klitgaard H, Bernardi G, Margineanu DG: Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 2001; 10(4):279-286
Fraser CM, Sills GJ, Forrest G, Thompson GG, Brodie MJ: Effects of anti-epileptic drugs on glutamine synthetase activity in mouse brain. Br J Pharmacol 1999; 126(7):1634-1638
Sills GJ, Leach JP, Fraser CM, Forrest G, Patsalos PN, Brodie MJ: Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur J Pharmacol 1997; 325(1):35-40
Loscher W, Honack D, Bloms-Funke P: The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res 1996; 735(2):208-216
Rigo JM, Hans G, Nguyen L, Rocher V, Belachew S, Malgrange B, Leprince P, Moonen G, Selak I, Matagne A, Klitgaard H: The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA-and glycine-gated currents. Br J Pharmacol 2002; 136(5):659-672
Poulain P, Margineanu DG: Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones. Neuropharmacology 2002; 42(3):346-352
French J, Edrich P, Cramer JA: A systematic review of the safety profile of levetiracetam: A new antiepileptic drug. Epilepsy Res 2001; 47(1–2):77-90
Goldberg JF, Burdick KE: Levetiracetam for acute mania. Am J Psychiatry 2002; 159(1):148
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ketter, T.A., Wang, P.W., Becker, O.V. et al. The Diverse Roles of Anticonvulsants in Bipolar Disorders. Ann Clin Psychiatry 15, 95–108 (2003). https://doi.org/10.1023/A:1024636309185
Issue Date:
DOI: https://doi.org/10.1023/A:1024636309185